Drug-eluting stents

Coronary disease

TCT 2018 | RESET: Everolimus DES vs. Sirolimus First Generation DES at Long Term

This study had published thrombosis and revascularization rates at one year after stenting, but today one year...

solaci - 5 October, 2018

Coronary disease

TCT 2018 | TALENT: Ultrathin Struts and Bioresorbable Polymer at the Lowest Possible Cost

This study assessed the Ultra-thin Strut Bioresorbable Polymer-based Coronary DES (Supraflex) against the Xience, with special emphasis...

solaci - 3 October, 2018

Coronary disease

TCT 2018 | SORT OUT IX: Polymer-Free DES with Ultra-Thin Struts vs. Bioresorbable Polymer- Based DES

Polymer persistence in 1st and 2nd generation DES meant to allow drug release has been associated with...

solaci - 3 October, 2018

Coronary disease

TCT 2018 | LEADERS FREE II: Polymer-Free DES in Patients at High Risk for Bleeding with 1 Month of Antiplatelet Therapy

This study was aimed at gaining device registration from the US Food and Drug Administration (FDA) for...

solaci - 3 October, 2018

Acute coronary syndromes

OCT Provides Hints About the Physiopathology Behind Very Late Stent Thrombosis

Neoatherosclerosis was frequently observed in patients who experienced very late stent thrombosis, particularly those with drug-eluting stents....

solaci - 10 September, 2018

Chronic Ischemic cardiopathy

The Dangerous Combination of Complex Angioplasty and High Bleeding Risk Seems to Have a Solution

The LEADERS FREE trial demonstrated that a polymer-free Biolimus A9-coated stent (BioFreedom™DCS; Biosensors Europe, Morges, Switzerland) is...

solaci - 21 August, 2018

Coronary disease

New Ultra-Thin-Strut DES: Do They Outperform Second-Generation DES?

The new drug-eluting stents (DES) equipped with ultra-thin struts are showing a lower risk of target lesion...

solaci - 5 July, 2018

Chronic Ischemic cardiopathy

EuroPCR 2018 | Ultimaster Registry: Difference in Strut Thickness

This work compared the safety and efficacy of angioplasty with thin-strut (80 µm) sirolimus-eluting stents with a cobalt...

solaci - 31 May, 2018

TCT 2018 | RESET: Everolimus DES vs. Sirolimus First Generation DES at Long Term

TCT 2018 | TALENT: Ultrathin Struts and Bioresorbable Polymer at the Lowest Possible Cost

TCT 2018 | SORT OUT IX: Polymer-Free DES with Ultra-Thin Struts vs. Bioresorbable Polymer- Based DES

TCT 2018 | LEADERS FREE II: Polymer-Free DES in Patients at High Risk for Bleeding with 1 Month of Antiplatelet Therapy

OCT Provides Hints About the Physiopathology Behind Very Late Stent Thrombosis

The Dangerous Combination of Complex Angioplasty and High Bleeding Risk Seems to Have a Solution

New Ultra-Thin-Strut DES: Do They Outperform Second-Generation DES?

EuroPCR 2018 | Ultimaster Registry: Difference in Strut Thickness

Últimas Noticias

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Is it really necessary to monitor all patients after TAVR?

Is it really necessary to monitor all patients after TAVR?

Noticias Institucionales

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

Accesos